Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial

William MacNee, Richard J Allan, Ieuan Jones, Maria Cristina De Salvo, Lisa F Tan

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic obstructive pulmonary disease (COPD) is a common lung disease leading to progressive decline in lung function. Inhibition of release of inflammatory mediators by p38 inhibitors may be a useful treatment for chronic inflammation of the airways thought to underlie the pathogenesis of the disease.
Original languageEnglish
Pages (from-to)738-45
Number of pages8
JournalThorax
Volume68
Issue number8
DOIs
Publication statusPublished - Aug 2013

Keywords

  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Benzamides
  • C-Reactive Protein
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Forced Expiratory Volume
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Disease, Chronic Obstructive
  • Pyridones
  • Retrospective Studies
  • Severity of Illness Index
  • Spirometry
  • Treatment Outcome
  • p38 Mitogen-Activated Protein Kinases

Fingerprint Dive into the research topics of 'Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial'. Together they form a unique fingerprint.

Cite this